New synthetic drugs outpace regulation efforts

Illicit labs are creating new synthetic drugs at a rapid speed, with compounds reaching the market long before health agencies know they exist.

The main point: New drug laws push chemists to invent new variants, modifying older drugs to create novel substances that are not outlawed.

New variants are prized because of their inexpensive production costs, high potency, and vague legal status. They can be made in labs all over the world, ordered online, and shipped anywhere. Because they are new compounds, they are difficult for law enforcement to detect. A small group of armchair chemists discuss ideas for new drugs and scour medical literature for forgotten molecules.
Why it’s important: These new substances emerge in the illicit drug market with untested potencies and effect, creating a cycle that is impossible to contain. And the new substances often have increased potency, which can make the substances more dangerous and addictive.

The details:

For example, adding a single oxygen atom to MDMA changes the molecule to methylone, which provides an Ecstasy-like euphoria. While MDMA has been illegal since 1985, when methylone reached the U.S. market in 2010, it could be sold legally in corner stores and smoke shops as “bath salts.”
Emergency rooms and poison control centers saw a huge increase in cases of the drug, and it was banned in 2011.
But: Chemists then tweaked the molecule to avoid the ban, creating new drug formulas. Illicit chemists now use methylone’s structure as a template. Methylone was an early example of a class of drugs known as synthetic cathinones, which continue to proliferate.
Nitazenes have been following a similar pattern, with new forms arising after China banned all variants of fentanyl in 2019. China banned nitazenes last year, which may cause production to shift to other molecules.

The bottom line: As one substance is controlled, another appears on the market.

Robyn Oster

Director of Policy

Published

April 2026

Family Resources